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Abstract 
Neither normal brain function nor the pathological processes involved in neurological 
diseases can be adequately understood without knowledge of the release, uptake and 
metabolism of glutamate. The reason for this is that glutamate (a) is the most abundant 
amino acid in the brain, (b) is at the cross-roads between several metabolic pathways, 
and (c) serves as the major excitatory neurotransmitter. In fact most brain cells express 
glutamate receptors and are thereby influenced by extracellular glutamate. In 
agreement, brain cells have powerful uptake systems that constantly remove glutamate 
from the extracellular fluid and thereby limit receptor activation. It has been clear since 
the 1970s that both astrocytes and neurons express glutamate transporters. However, 
the relative contribution of neuronal and glial transporters to the total glutamate uptake 
activity, however, as well as their functional importance, has been hotly debated ever 
since. The present short review provides (a) an overview of what we know about 
neuronal glutamate uptake as well as an historical description of how we got there, and 
(b) a hypothesis reconciling apparently contradicting observations thereby possibly 
resolving the paradox.  
 
ABBREVIATIONS 
Cre, Cyclization recombinase (Le and Sauer, 2000); EAAC1, glutamate transporter 
(EAAT3; slc1a1; Kanai and Hediger, 1992; Bjørås et al., 1996); EAAT, excitatory amino 
acid transporter (synonym to glutamate transporter); GABA, γ-aminobutyric acid; 
GLAST, rat glutamate transporter (EAAT1; slc1a3; Storck et al., 1992; Tanaka, 1993a); 
GLT-1, rat glutamate transporter (EAAT2; slc1a2; Pines et al., 1992); GLUL, glutamine 
synthetase; TBOA, DL-threo-β-benzyloxyaspartate 
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Abstract 
Neither normal brain function nor the pathological processes involved in neurological 
diseases can be adequately understood without knowledge of the release, uptake and 
metabolism of glutamate. The reason for this is that glutamate (a) is the most abundant 
amino acid in the brain, (b) is at the cross-roads between several metabolic pathways, 
and (c) serves as the major excitatory neurotransmitter. In fact most brain cells express 
glutamate receptors and are thereby influenced by extracellular glutamate. In 
agreement, brain cells have powerful uptake systems that constantly remove glutamate 
from the extracellular fluid and thereby limit receptor activation. It has been clear since 
the 1970s that astrocytes and neurons express glutamate transporters. The relative 
contribution of neuronal and glial transporters to the total glutamate uptake activity, 
however, as well as their functional importance, has been hotly debated ever since. The 
present short review provides (a) an overview of what we know about neuronal 
glutamate uptake as well as an historical description of how we got there, and (b) an 
hypothesis reconciling apparently contradicting observations thereby possibly resolving 
the paradox.  
 
ABBREVIATIONS 
Cre, Cyclization recombinase (Le and Sauer, 2000); EAAC1, rabbit glutamate 
transporter (EAAT3; slc1a1; Kanai and Hediger, 1992); EAAT, excitatory amino acid 
transporter (synonym to glutamate transporter); GABA, γ-aminobutyric acid; GLAST, rat 
glutamate transporter (EAAT1; slc1a3; Storck et al., 1992; Tanaka, 1993a); GLT-1, rat 
glutamate transporter (EAAT2; slc1a2; Pines et al., 1992); GLUL, glutamine synthetase; 
TBOA, DL-threo-β-benzyloxyaspartate 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
3 
 
1. Introduction 
It was noted early on that glutamate is a key player in brain metabolism (Krebs, 1935) 
and that brain cells have a remarkable ability to take up glutamate from the extracellular 
fluid (Stern et al., 1949). Unexpectedly, glutamate was found to have an excitatory 
effect on neurons (Hayashi, 1954; Lucas and Newhouse, 1957; Curtis et al., 1959; 
Curtis et al., 1960) and investigators started to speculate whether glutamate might be a 
neurotransmitter (for review see: Roberts et al., 1981; Schousboe, 1981; Danbolt, 2001; 
Watkins and Evans, 1981; Fonnum, 1984; Erecinska and Silver, 1990; Broman et al., 
2000; McKenna, 2007; Hertz, 2013). As glutamate uptake turned out to be the only 
mechanism able to remove extracellular glutamate, it followed that the brain had to be 
dependent on glutamate uptake in order to control the excitatory action of glutamate 
(Logan and Snyder, 1971; Logan and Snyder, 1972; Wofsey et al., 1971; Balcar and 
Johnston, 1972; Johnston, 1981). In agreement, glutamate uptake was shown to protect 
neurons in culture against glutamate (Frandsen and Schousboe, 1990; Rosenberg et al., 
1992). This realization lead to a strong interest in glutamate uptake as perturbations in 
glutamate uptake might cause or aggravate neurological disease. For instance, 
because the uptake process is driven by the transmembrane ion gradients of K+ and 
Na+(Kanner and Schuldiner, 1987; Nicholls and Attwell, 1990; Barbour et al., 1991; 
Danbolt, 2001), it follows that a compromised brain energy supply (e.g. ischemia) will 
impair the transport process (for review see: Szatkowski and Attwell, 1994; Rossi et al., 
2000; Danbolt, 2001; Larsson et al., 2004; Grewer and Rauen, 2005; Tzingounis and 
Wadiche, 2007). A full discussion about molecular properties and roles of glutamate 
transporters in disease, however, is beyond the scope of this review as that topic is 
covered elsewhere (for review see for example: Lipton and Rosenberg, 1994; Danbolt, 
2001; Sattler and Rothstein, 2006; Beart and O'Shea, 2007; Sheldon and Robinson, 
2007; Bröer and Palacin, 2011; Vandenberg and Ryan, 2013; Robert and Sontheimer, 
2014; Robert et al., 2014; Karki et al., 2015; Soni et al., 2014; Takahashi et al., 2015).  
 Relevant to the present review is the fact that both glial cells (e.g. Henn et al., 
1974) and neurons (their axon-terminals in particular; Wofsey et al., 1971; Beart, 1976) 
possess high-affinity glutamate uptake mechanisms. This was clear already in the 
1970s, but the relative importance of the neuronal (axon-terminal) and the astroglial 
uptake systems has been debated ever since.  
 
2. Early observations of neuronal glutamate uptake 
Evidence for significant glutamate uptake in neurons came from several sources: (a) It 
was noted that neurons cultured alone are able to take up glutamate with high affinity 
(e.g. Drejer et al., 1982; Waniewski and Martin, 1983; Sher and Hu, 1990; Frandsen 
and Schousboe, 1990; Balcar, 1991; Wang et al., 1998a; Plachez et al., 2004). (b) 
Axon-terminals are believed to reseal during homogenization of brain tissue and thereby 
form metabolically active structures. These pinched off nerve endings are called 
"synaptosomes" (Gray and Whittaker, 1962; Whittaker, 1969), and they can be used in 
uptake assays (Gfeller et al., 1971; Logan and Snyder, 1972; Levi and Raiteri, 1973a; 
Levi and Raiteri, 1973b; Dodd et al., 1981; Erecinska et al., 1996; Robinson, 1998; 
Raiteri and Raiteri, 2000). Although it was understood that fragments of some of the 
smallest astrocyte branches can reseal like axon-terminals, and that this would 
contaminate the synaptosome preparations (e.g. Delaunoy et al., 1979; Henn et al., 
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1976; Nakamura et al., 1993), it was believed that the resealing frequency of astrocytes 
was lower than that of axon-terminals. If so, then neuronal uptake would be relatively 
better preserved in the homogenates than that of other cell types. (c) Radiolabeled 
excitatory amino acids (L-[3H]glutamate and D-[3H]aspartate) accumulated preferentially 
in nerve terminals also when presented to brain slices in vitro (Beart, 1976; Storm-
Mathisen and Iversen, 1979; Taxt and Storm-Mathisen, 1984), or infused in vivo at low 
concentrations and for short duration (Storm-Mathisen and Wold, 1981). While a 
predominance of neuronal over astroglial uptake in synaptosome preparations could be 
disregarded as a consequence of differences in cellular geometry and thereby in 
resealing frequency (see section 10 below), a predominance of neuronal uptake in 
hippocampal slices was harder to explain without assuming that axon-terminals had a 
considerable uptake activity. (d) Interruption of putative glutamatergic fibers caused a 
marked decrease in glutamate uptake activity in the target regions of these fibers (Fig. 
1). The uptake activities in the target areas were determined using synaptosomes or 
brain slices (Divac et al., 1977; McGeer et al., 1977; Storm-Mathisen, 1977; Fonnum et 
al., 1981; Taxt and Storm-Mathisen, 1984). Thus, destruction of neuronal cell bodies led 
to reduced glutamate uptake far away from the site of the lesion. Based on this it was 
assumed that the reductions in uptake activity were due to loss of nerve terminals rather 
than of astrocytes. (e) Selective retrograde labeling of neurons was observed after D-
[3H]aspartate microinjections or implantations further arguing that neuronal uptake was 
high relative to the astroglial uptake (Baughman and Gilbert, 1980; Streit, 1980; Fischer 
et al., 1986).  
 These studies reinforced each other, and some investigators even thought that 
high-affinity glutamate uptake was the best marker for identification of glutamatergic 
nerve terminals (for review see: Fonnum, 1984; Ottersen and Storm-Mathisen, 1984). 
However, weaknesses in the arguments (see below) were highlighted after the 
glutamate transporters were cloned and localized. 
 
3. Identification of plasma membrane glutamate transporters 
The first glutamate transporter to be purified in active form (Danbolt et al., 1990) was 
the one now known as EAAT2 (GLT-1; slc1a2; Pines et al., 1992). The purification was 
based on solubilization of rat brain membranes with a detergent (cholate) followed by 
fractionation using conventional chromatographic techniques. Because the transporters 
could only be identified by their transport function, reconstitution of transport activity in 
artificial cell membranes (liposomes) was the only way to assay the various protein 
fractions for transporter content (Danbolt et al., 1990). This approach resulted in a 
preparation of a glutamate transporter protein which was later confirmed to be pure 
although it was only enriched about hundred times (Levy et al., 1993; Lehre and 
Danbolt, 1998). In fact, EAAT2 was found to represent 1 % of the total forebrain protein 
(Lehre and Danbolt, 1998). Antibodies were raised to the purified protein and used to 
localize it in the brain (Danbolt et al., 1992; Levy et al., 1993) and to screen expression 
libraries (Pines et al., 1992). Simultaneously, but independently of each other, three 
other research teams succeeded in cloning another two glutamate transporters using 
completely different approaches: EAAT1 (GLAST; slc1a3; Storck et al., 1992; Tanaka, 
1993a) and EAAT3 (EAAC1; slc1a1; Kanai and Hediger, 1992; Kanai et al., 1993; 
Bjørås et al., 1996). The three human counterparts were quickly identified (Arriza et al., 
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1994). Another two glutamate transporters were found later: EAAT4 (slc1a6; Fairman et 
al., 1995) and EAAT5 (slc1a7; Arriza et al., 1997). Thus, the mammalian genome 
contains five glutamate (or excitatory amino acid) transporter genes (for review see for 
instance: Danbolt, 2001; Beart and O'Shea, 2007; Tzingounis and Wadiche, 2007; Zhou 
and Danbolt, 2013; Vandenberg and Ryan, 2013; Grewer et al., 2014; Fontana, 2015). 
 All the EAATs catalyze coupled transport of 1H+, 3Na+, and 1K+ with 1 substrate 
molecule (Klöckner et al., 1993; Zerangue and Kavanaugh, 1996a; Levy et al., 1998; 
Owe et al., 2006). L-Glutamate and DL-aspartate are transported with similar affinities 
while D-glutamate is not. The transporters are actually complex molecules as they also 
function as chloride channels (Fairman et al., 1995; Zerangue and Kavanaugh, 1996a, 
Wadiche et al., 1995a; Wadiche et al., 1995b; Wadiche and Kavanaugh, 1998; Bergles 
et al., 2002; Koch et al., 2007; Ryan and Mindell, 2007; Zhou et al., 2014a; Fahlke et al., 
2016; LeVine et al., 2016) and even transport water (MacAulay et al., 2001, MacAulay 
et al., 2004). Although the mammalian transporters have not yet been crystallized, we 
know quite a lot about their structure (Kanner, 2007; Vandenberg and Ryan, 2013; 
Gouaux, 2009; Verdon et al., 2014; Silverstein et al., 2015; Fahlke et al., 2016; LeVine 
et al., 2016).  
 The functional properties differ between the subtypes (Tzingounis and Wadiche, 
2007; Vandenberg and Ryan, 2013). EAAT1-3 resemble each other in that they have 
relatively short cycling times and fairly similar affinities (Grewer and Rauen, 2005, Otis 
and Kavanaugh, 2000, Bergles et al., 2002). The Km values reported for L-glutamate 
transport by EAAT1 are typically in the range 7-20 µM (Arriza et al., 1994; Wadiche and 
Kavanaugh, 1998; Klöckner et al., 1993). The corresponding values for EAAT2 and 
EAAT3 are, respectively, 12-18 µM (Arriza et al., 1994; Levy et al., 1998; Bergles et al., 
2002) and 8-30 µM (Arriza et al., 1994; Kanai et al., 1994; Kanai and Hediger, 1992; 
Grewer et al., 2000). The kinetics of EAAT4 and EAAT5 are quite different (Mim et al., 
2005; Gameiro et al., 2011). EAAT4 has the highest affinity with reported Km values in 
the range 0.6-3.3 µM (Fairman et al., 1995; Lin et al., 1998; #19512}; Mim et al., 2005), 
while EAAT5 has the lowest affinity with Km values in the range 61-63 µM (Gameiro et 
al., 2011; Schneider et al., 2014).  
 
4. Heterogeneity of glutamate uptake 
A heterogeneity in the glutamate uptake system was expected early on based on 
differences between various cell cultures and tissue preparations with respect to 
substrate selectivity (Ferkany and Coyle, 1986; Robinson et al., 1991; Robinson et al., 
1993; Fletcher and Johnston, 1991; Balcar and Li, 1992; Rauen et al., 1992). A detailed 
account of the substrate selectivity of the individual transporter is beyond the scope of 
the present review. For more information, we recommend the outstanding review by 
Bridges and co-workers as an introduction (Bridges et al., 1999) and more recent 
reviews for the latest updates (e.g. Vandenberg et al., 1997; Jensen and Bräuner-
Osborne, 2004; Shigeri et al., 2004; Bridges and Esslinger, 2005; Shimamoto and 
Shigeri, 2006; Shimamoto, 2008; Sagot et al., 2008; Jensen et al., 2009). Here we will 
only point out (a) that the commonly used uptake inhibitor dihydrokainate (DHK; CAS 
52497-36-6) blocks EAAT2 with high selectivity over the other EAATs (Arriza et al., 
1994; Bridges et al., 1999), and (b) that DL-threo-β-benzyloxyaspartate (TBOA; CAS 
205309-81-5) and its variants (e.g. PMB-TBOA and TFB-TBOA) block all five of the 
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EAATs (Bridges et al., 1999; Lebrun et al., 1997; Shimamoto et al., 1998; Shimamoto, 
2008). These compounds are competitive inhibitors in the sense that they bind to the 
same binding sites as glutamate thereby competing with glutamate for binding to the 
transporter protein. Importantly, although DHK and TBOA can bind to the transporter 
like glutamate, they are too bulky to be moved through the transporter to the other side 
of the plasma membrane. In contrast, several other glutamate uptake inhibitors, e.g. D-
aspartate, threo-3-hydroxyaspartate (CAS 7298-99-9; Balcar et al., 1977) and L-trans-
pyrrolidine-2,4-dicarboxylate (CAS 64769-66-0; Bridges et al., 1991) are themselves 
transported. This means that they inhibit uptake of glutamate by being transported 
instead of glutamate, but, importantly, they are also exchanged (see Section 12 below) 
with internal glutamate and thereby induce glutamate release. Thus, when transportable 
uptake inhibitors are added to cell cultures, the extracellular glutamate concentration 
rises both because the extracellular glutamate is not removed and because more 
glutamate is coming out of the cells (Volterra et al., 1996; O'Shea et al., 2002).  
 
5. Cellular distribution of glutamate transporters 
Early studies on the distribution of glutamate uptake sites were based on 
autoradiography of radioactively labeled substrates or on the use of antibodies to 
substrates immobilized in the tissue by means of glutaraldehyde fixation (for review see: 
Zhou and Danbolt, 2014). After the transporters had been cloned and the sequences 
were known, transporter mRNA could be detected using in-situ hybridization (Harrison 
and Pearson, 1990; Berger and Hediger, 1998). Further, peptides representing parts of 
the transporter proteins could be synthesized and used to generate antibodies to the 
transporters themselves (Lehre et al., 1995; Danbolt et al., 1998) rather than to the 
substrates. Antibodies became readily available and a large number of papers were 
published. Unfortunately, not all antibodies and procedures were validated well enough 
(for discussion see: Holmseth et al., 2005; Holmseth et al., 2006; Rhodes and Trimmer, 
2006; Lorincz and Nusser, 2008; Couchman, 2009; Kalyuzhny, 2009; Holmseth et al., 
2012a; Zhou et al., 2014b).  Further, rapid post mortem proteolysis of the termini 
of EAAT1 and EAAT2 represents an additional challenge when studying human 
samples (Beckstrøm et al., 1999; Tessler et al., 1999; Li et al., 2012). Most of the 
immunoreactivity to the C-terminus of EAAT2 is gone after 24 hours and there is a 
significant reduction after 12 hours. The reduction is, however, not uniform, but happens 
apparently suddenly in each cell leaving entire astrocyte domains unlabeled. Further, 
EAAT1 is lost at a slower rate. At 12 hours a patchy image appears with many 
astrocytes not labeled for any of the transporters and some only positive for EAAT1. A 
very different pattern is seen with antibodies to the central parts of the EAAT2 protein 
which is much more stable (Li et al., 2012). Consequently, the literature on transporter 
distributions is complex. 
 
5.1. EAAT2 (GLT-1; slc1a2) was the first glutamate transporter to be localized 
immunocytochemically (Danbolt et al., 1992; Lehre et al., 1993; Levy et al., 1993; Lehre 
et al., 1995). The astrocytes were intensely labeled, while the neurons appeared 
unlabeled. Labeling was not even detected in glutamatergic axon-terminals in the 
stratum radiatum of the CA1 hippocampus (Danbolt et al., 1992; Lehre et al., 1995) 
despite high levels of EAAT2 mRNA in CA3 pyramidal cells from which they originate 
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(Torp et al., 1994; Schmitt et al., 1996; Torp et al., 1997). Subsequent 
immunocytochemical studies confirmed this conclusion (e.g. Rothstein et al., 1994; 
Schmitt et al., 1996; Milton et al., 1997; Kugler and Schmitt, 2003; Berger et al., 2005; 
Holmseth et al., 2009), while in-situ hybridization studies added that EAAT2 mRNA was 
also present in several neuronal populations (Berger and Hediger, 1998; Berger and 
Hediger, 2000; Berger and Hediger, 2001). Data obtained with EAAT2 eGFP BAC 
reporter mice (De Vivo et al., 2010a) showed that the EAAT2 promotor is highly active 
in virtually all astrocytes (defined as cells expressing glial fibrillary acidic protein, GFAP), 
but also in several neuronal populations (including 80 % of the CA3 pyramidal cells), 
albeit at considerably lower levels than in astrocytes. This is in fairly good agreement 
with the in situ hybridization data (e.g. Berger and Hediger, 1998; Berger and Hediger, 
2000; Berger and Hediger, 2001).  
 The failure to detect EAAT2 protein in neurons in the mature and normal brain 
was puzzling as both EAAT2 protein and mRNA were detected in several types of 
cultured neurons (e.g. Brooks-Kayal et al., 1998; Mennerick et al., 1998; Meaney et al., 
1998; Wang et al., 1998a; Plachez et al., 2000). Further, EAAT2 had also been reported 
in neurons in the normal and mature mammalian retina (Rauen, 2000; Harada et al., 
1998), transiently in growing axons of the mouse spinal cord before establishing 
astrocytic expression (Yamada et al., 1998), and in brain neurons after hypoxia-
ischemia (Martin et al., 1997). Although it is to be expected that the behavior of cells in 
the normal and mature brain may differ from that of cells in culture or in diseased tissue 
(Cahoy et al., 2008), this did not explain why many neurons in the mature brain express 
EAAT2 mRNA. Why couldn't the EAAT2 protein be detected? Could it be that EAAT2 
mRNA had additional functions? After all, the length of the mRNA molecule was 11.3 kb 
or 6.6 times longer than the coding sequence (Pines et al., 1992).  
 Adding to the puzzle, immunoprecipitation experiments showed that antibodies to 
EAAT2 could remove about 95 % of the total reconstitutable glutamate uptake activity in 
detergent (cholate) extracts from the normal young adult rat brain (Danbolt et al., 1992; 
Haugeto et al., 1996). In agreement, deletion of the EAAT2 gene in mice caused an 
almost complete loss (about 95 %) of glutamate uptake activity (Tanaka et al., 1997; 
Otis and Kavanaugh, 2000; Matsugami et al., 2006; Kiryk et al., 2008; Holmseth et al., 
2012b; Zhou et al., 2014b). 
  Homozygote EAAT2-knockout mice (Tanaka et al., 1997) are inconspicuous at 
birth because EAAT2 expression is very low in newborn rats and mice (Ullensvang et al., 
1997; Furuta et al., 1997; Hanson et al., 2015), but they become spontaneously 
epileptic at around three weeks of age and about half of them have died by the end of 
the fourth week (Tanaka et al., 1997; Mitani and Tanaka, 2003; Takasaki et al., 2008). A 
selective deletion of EAAT2 in the brain is sufficient to reproduce this phenotype 
confirming that EAAT2 plays its most important role in the brain (Zhou et al., 2014b). 
The heterozygote EAAT2 knockout mice (+/-) have only half the EAAT2-concentrations 
as wildtype mice, but do not show any apparent morphological brain abnormalities 
(Kiryk et al., 2008). However, they are more vulnerable to traumatic spinal cord injury 
(Lepore et al., 2011).   
 The high total expression levels of glutamate transporters (Bergles and Jahr, 
1997; Dehnes et al., 1998; Lehre and Danbolt, 1998; Otis and Kavanaugh, 2000) make 
sense when taking into account that low resting levels of extracellular glutamate are 
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obtained (Herman and Jahr, 2007) despite the slowness of the transport process (Otis 
and Jahr, 1998; Otis and Kavanaugh, 2000; Bergles et al., 2002; Grewer and Rauen, 
2005) and the rapid extracellular turnover of glutamate (Jabaudon et al., 1999). The 
average number of EAAT-type of protein molecules is more than ten thousand per 
synapse (Table 1). 
 Given that EAAT2 was purified by monitoring uptake activity (Danbolt et al., 
1990), it was not surprising that EAAT2 is the major isoform, but such a dominant role 
was unexpected. Further, it was also hard to explain why the synaptosomal uptake 
activity was absent in the EAAT2 knockout mice (Tanaka et al., 1997) considering that 
the protein had only been detected in astrocytes. This needed an explanation (see 
below). 
  
5.2. EAAT1 (Storck et al., 1992; Tanaka, 1993b; Arriza et al., 1994) is the only 
glutamate transporter that appears to be selectively expressed in astroglial cells in the 
central nervous system (Danbolt, 1994; Lehre et al., 1993; Lehre et al., 1995; Ginsberg 
et al., 1995; Rothstein et al., 1995; Schmitt et al., 1997; Ullensvang et al., 1997; Berger 
and Hediger, 1998; Banner et al., 2002; Kugler and Beyer, 2003; Regan et al., 2007; 
Berger and Hediger, 2000; Jungblut et al., 2012) including retina (Rauen et al., 1996; 
Lehre et al., 1997; Rauen et al., 1998; Harada et al., 1998; Pow and Barnett, 1999; 
Rauen, 2000; Bringmann et al., 2013). It is also expressed in supporting cells in the 
inner ear (Furness and Lehre, 1997; Takumi et al., 1997) as well as in several 
peripheral organs including, the heart, fat cells and taste buds (Lawton et al., 2000; 
Berger and Hediger, 2006; Adachi et al., 2007; Martinov et al., 2014). Mice lacking 
EAAT1 (Watase et al., 1998) have an increased prenatal lethality, but appear to develop 
normally after birth. They show, however, symptoms of insufficient glutamate uptake in 
regions where EAAT1 is the major glutamate transporter, e.g. cerebellum, inner ear and 
retina (Watase et al., 1998; Hakuba et al., 2000; Harada et al., 1998; for more 
references see: Zhou and Danbolt, 2014). Lack of EAAT1 is thereby less dramatic than 
lack of EAAT2 (see above), but as the expression is not neuronal it will not be 
discussed further in this review.  
 
5.3. EAAT3 (Kanai and Hediger, 1992; Arriza et al., 1994; Bjørås et al., 1996) is a 
neuronal transporter as originally suggested and it is not expressed in glial cells 
(Rothstein et al., 1994; Shashidharan et al., 1997; Holmseth et al., 2012b). It appears to 
be expressed in most, if not all, neurons throughout the CNS. However, EAAT3 is not 
found in axon-terminals, and is selectively targeted to somata and dendrites 
(Shashidharan et al., 1997; Cheng et al., 2002; Holmseth et al., 2012b). Within the CNS, 
EAAT3 is found in the highest concentrations in the hippocampus followed by the 
neocortex, but the total tissue content in young adult rat brains is about 100 times lower 
than that of EAAT2 (Holmseth et al., 2012b).  
 Mice lacking EAAT3 (Peghini et al., 1997) develop dicarboxylic aminoaciduria 
and have been reported to age prematurely (Aoyama et al., 2006) possibly because 
EAAT3 transports cysteine (Zerangue and Kavanaugh, 1996b) which is needed for 
glutathione synthesis. However, EAAT3-deficient mice do not show signs of 
neurodegeneration at a young age and do not have epilepsy (Peghini et al., 1997; 
Aoyama et al., 2006; Berman et al., 2011) in agreement with the low expression levels 
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compared to EAAT2. Humans lacking EAAT3 develop dicarboxylic aminoaciduria in 
agreement with the studies on mice (Bailey et al., 2011), and human EAAT3 
polymorphisms have been reported to be associated with obsessive–compulsive 
disorders (Brandl et al., 2012; Walitza et al., 2010; Grunblatt et al., 2014). 
 EAAT3 has been particularly difficult to localize and, there are conflicting reports 
in the literature. The difficulties are in part due to the lower expression levels (Zhou and 
Danbolt, 2014), but mostly to the difficulties involved in obtaining specific antibodies (for 
discussions see: Danbolt et al., 1998; Holmseth et al., 2005; Holmseth et al., 2006). It 
was not possible to distinguish between specific labeling of EAAT3 and cross-reactivity 
until tissue from the EAAT3-deficient mice became available (Peghini et al., 1997). The 
so-called pre-adsorption test to validate antibody specificity did not help (Holmseth et al., 
2012a). 
 
5.4. EAAT4 and EAAT5 are, as already mentioned above, quite different from the other 
EAATs. They transport slowly and have very high chloride conductances (Mim et al., 
2005; Gameiro et al., 2011).  
 EAAT4 (Fairman et al., 1995) is expressed at fairly high levels in the dendrites 
and cell bodies belonging to the cerebellar Purkinje cells as well as in some forebrain 
neurons, but not in non-neuronal cells (Dehnes et al., 1998; Massie et al., 2008). This 
distribution pattern has been confirmed by using EAAT4 promotor reporter mice (Gincel 
et al., 2007; De Vivo et al., 2010b). There is also EAAT4 in vestibular hair cells and 
calyx endings (Dalet et al., 2012). EAAT4 is thereby considered to be neuron selective 
(apart from expression in vestibular hair cells), but it does not appear to be of critical 
importance as EAAT4 knockout mice are viable and appear normal (Huang et al., 2004) 
albeit with some alteration of receptor activation (Nikkuni et al., 2007). Although EAAT4 
in Purkinje cells removes more glutamate than EAAT3, EAAT4 is removing less than 
10% of the glutamate released by the climbing fibers (Huang et al., 2004). 
 EAAT5 (Arriza et al., 1997) is present in the retina at significant levels (Eliasof et 
al., 1998; Veruki et al., 2006; Schneider et al., 2014), and it may be subject to variable 
splicing (Lee et al., 2012), but has not been reported in other parts of the central 
nervous system. It is present in vestibular hair cells (Dalet et al., 2012), in the heart 
(Arriza et al., 1997; Martinov et al., 2014), in skeletal muscle (Arriza et al., 1997) and 
possibly at low levels in several other peripheral organs (Lee et al., 2013).    
 
6. Weaknesses in the old evidence for neuronal glutamate uptake 
When the first immunocytochemical data appeared on the distribution of the various 
glutamate transporters, it became clear the transporter in glutamatergic nerve terminals 
had not been identified (Danbolt, 2001). Of course, a novel transporter with similar 
properties might still remain undiscovered, but EAAT2 could (as explained in Section 
5.1 above) account for almost all of the uptake activity giving little room for hypothetical 
undiscovered glutamate transporters: (a) Antibodies to the glutamate transporter 
subtype EAAT2 could immunoprecipitate most of the reconstitutable glutamate uptake 
activity present in brain extracts (see Section 5.1 for references). (b) Synaptosomes 
prepared from EAAT2-deficient mutant mice had very low uptake activities (see Section 
5.1 for references). (c) Lesioning of glutamatergic pathways resulted in down-regulation 
of glial glutamate transporters in the target region, and thereby had effects that were not 
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limited a simple loss of axon-terminals (Fig. 1; Levy et al., 1995; Ginsberg et al., 1995; 
Rao et al., 1998). This observation indicated that glial expression of glutamate 
transporters depends, at least in part, on soluble factors (Fig. 2; Gegelashvili et al., 
1997; Gegelashvili et al., 2000; Plachez et al., 2000; Martinez-Lozada et al., 2016). In 
other words, investigators asked if the reductions in synaptosomal uptake observed in 
the target areas of lesioned fibers could be attributed to a loss of glial uptake sites. (d) 
The glutamate uptake in neuronal cultures (Wang et al., 1998b) and in synaptosome 
preparations was shown to be sensitive to inhibition by kainate and dihydrokainate 
(Johnston et al., 1979; Robinson et al., 1993; Bridges et al., 1999) just like EAAT2 
which is the only glutamate transporter that is sensitive to inhibition by these 
compounds (Arriza et al., 1994; Martinez-Lozada et al., 2016). (e) Also the 
autoradiographic studies aimed at localizing the glutamate uptake sites in hippocampal 
slices could be criticized because they were either (Beart, 1976; Storm-Mathisen and 
Iversen, 1979) done at the electron microscopical level with [3H]glutamate (which may 
be converted to [3H]glutamine in glial cells and then back to [3H]glutamate in the 
terminals or (Taxt and Storm-Mathisen, 1984) with D-[3H]aspartate at the light 
microscopical level where labeling of terminals cannot be rigorously distinguished from 
labeling of surrounding fine glial processes.  
 Based on the above, there was good reason to question (Bridges et al., 1999; 
Koch et al., 1999) if the synaptosomal uptake is due to uptake in glial cell fragments 
contaminating these preparations (Henn et al., 1976; Nakamura et al., 1993) rather than 
to uptake in the synaptosomes (nerve terminals) themselves. 
 
7. Axon-terminals take up glutamate by means of EAAT2 
As explained above (see Section 6), the very existence of a high affinity glutamate 
uptake mechanism in nerve terminals was questioned. To address the question directly 
avoiding the above weaknesses, it was decided to develop antibodies specifically 
recognizing glutaraldehyde-fixed D-aspartate (Zhang et al., 1993). These antibodies 
reacted strongly with D-aspartate without cross-reacting with other relevant amino acids 
like L-aspartate, glutamine and L-glutamate (Zhang et al., 1993; Gundersen et al., 1993) 
or with aldehyde fixed brain tissue in general. D-aspartate was chosen because (a) it is 
a substrate for the EAAT-type of transporters; (b) there is hardly any D-aspartate 
present endogenously; (c) exogenously added D-aspartate is slowly metabolized in the 
adult brain (Davies and Johnston, 1976; Takagaki, 1978). Thus, detection of sodium-
dependent high affinity uptake of D-aspartate in neurons would be proof of direct uptake 
rather than indirect uptake via astrocytes (c.f. glutamate-glutamine cycle).  
 Hippocampal slices were incubated with D-aspartate, fixed with glutaraldehyde 
and processed for immunogold-labeling with the anti-D-aspartate antibodies. By 
electron microscopy it could be shown that D-aspartate accumulated in a sodium 
dependent manner in glutamatergic terminals in rat stratum radiatum in hippocampus 
CA1 (Gundersen et al., 1993) and in rat striatum (Gundersen et al., 1996). This implied 
that terminals did have the ability to take up glutamate (Fig. 3), but the identity of the 
transporter responsible was still unknown. After the discovery that dihydrokainate is a 
selective inhibitor of EAAT2 (Arriza et al., 1994), it was decided to repeat the slice 
experiments. Then it turned out that the accumulation of D-aspartate in the terminals 
could be blocked by adding dihydrokainate together with D-aspartate (Furness et al., 
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2008). Further, using hippocampal slices from the EAAT2-knockout mice (Tanaka et al., 
1997) it became clear that there was no D-aspartate uptake in axon-terminals in CA1 in 
mice lacking the EAAT2 gene (Furness et al., 2008). 
 We also examined D-aspartate uptake in hippocampal synaptosome 
preparations in the same way (Furness et al., 2008). About 70 % of the nerve terminals 
in these preparations were D-aspartate positive, and they represented 85 % of the D-
aspartate immunoreactivity implying that most of the uptake was due to terminals.   
 These experiments showed that axon-terminals accumulate D-aspartate by a 
sodium-dependent mechanism that is sensitive to inhibition by dihydrokainate and that 
depends on the EAAT2-gene. This strongly suggested that EAAT2 is the glutamate 
transporter in nerve terminals. However, one important piece of evidence was still 
missing: EAAT2 protein had not been detected in the terminals. 
 
8. EAAT2 protein in axon-terminals 
Could EAAT2 be expressed in axon-terminals and somehow have evaded detection? 
One possibility could be splice variants (Lauriat and Mcinnes, 2007) not recognized by 
the antibodies, although the available array of anti-EAAT2 antibodies recognizing 
different parts of the EAAT2 molecule made that somewhat unlikely (see: Holmseth et 
al., 2005; Holmseth et al., 2009). Nevertheless, this was a possibility considering that 
there are multiple EAAT2 splice variants (e.g. Meyer et al., 1998a; Meyer et al., 1998b; 
Meyer et al., 1998c; Honig et al., 2000; Flowers et al., 2001; Berger et al., 2005; 
Sullivan et al., 2004; Rauen et al., 2004; Peacey et al., 2009). One of these variants 
might be selective for the axon-terminals. In fact, it was first thought that EAAT2b (GLT-
1b) was the neuronal transporter, but it was later realized that the antibodies had not 
been good enough, and that EAAT2a might be the one in terminals (Chen et al., 2004). 
It is now recognized that both EAAT2a and EAAT2b are predominantly astroglial 
(Berger et al., 2005; Holmseth et al., 2009), and that the total tissue content of EAAT2a 
protein is one order of magnitude higher than that of EAAT2b (Holmseth et al., 2009). 
Thus, EAAT2a is the predominant variant both in astroglia and in axon-terminals 
(Furness et al., 2008; Holmseth et al., 2009) in agreement with Chen and co-workers 
(2004).  
 The study by Chen and co-workers (2004) was based on pre-embedding electron 
microscopy and was not quantitative beyond determination of the number cell profiles 
with labeling significantly above background (for a description of these methods see: 
Danbolt et al., 1998; Amiry-Moghaddam and Ottersen, 2013). It was therefore important 
to do post-embedding immuno-gold which permits comparisons of labeling intensities. A 
limitation with the latter technique, however, is that the gold-particles attached to 
antibodies can swing around and thereby be located quite some distance from the 
antigen. Therefore if plasma membranes from two different cells are too close to each 
other, then it may not be possible to use immuno-gold to determine which cell the 
antigen belongs to (Danbolt et al., 1998; D'Amico and Skarmoutsou, 2008; Amiry-
Moghaddam and Ottersen, 2013). Fortunately, the hippocampal slice preparations used 
(Furness et al., 2008) had an advantage over perfusion fixed tissue (Danbolt et al., 
1998): namely that the extracellular spaces were larger and, interestingly, quite similar 
to tissue prepared by high-pressure freezing techniques (Korogod et al., 2015). Thus, 
the distance between neighboring plasma membranes was greater and frequently 
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further than the mobility of the gold-particles. This was very helpful because it became 
easier to interpret the immuno-gold labeling. About 80 % of the gold-particles were 
found to be associated with astroglia. The rest was distributed over other structures. 
About 6 % was in nerve terminal membranes, while most the remainder was distributed 
over small axons (Furness et al., 2008). These data are from the young adult rat 
stratum radiatum hippocampus CA1. Interestingly, the total amounts of plasma 
membranes in the stratum radiatum per cubic micrometer of tissue was 14 square 
micrometer of which about 10 % belonged to astrocytes, about 10 % to dendritic spines 
and about 10 % to terminals, while most of the remainder was due to small axons 
(Lehre and Danbolt, 1998; Furness et al., 2008; Holmseth et al., 2012b). Thus, the 
EAAT2 density over terminals was about 10 % of that over astroglia. This is still about 
ten times higher than the density of EAAT3 in dendritic spines and dendrites (Holmseth 
et al., 2012b). As mentioned above, EAAT3 is absent from axon-terminals.  
 Because the glutamatergic terminals in the stratum radiatum CA1 originate 
mostly from the CA3 pyramidal cells, it makes sense that the latter cells have high 
levels of EAAT2 mRNA in agreement with recent observation from EAAT2 eGFP BAC 
reporter mice (De Vivo et al., 2010a) as well as with in-situ hybridization studies (for 
references, see above).  
 
9. Astroglial EAAT2 is the major protector against excitotoxicity 
As explained above, EAAT2 is expressed both in astrocytes and in axon-terminals, and 
there is no available method to distinguish between neuronal and astroglial EAAT2 
pharmacologically. Further, in the conventional (or global) EAAT2-knockout mice 
(Tanaka et al., 1997) the EAAT2 gene was deleted from conception onwards in all cells 
(thus in both neurons and glia as well as in peripheral organs). Therefore, the obvious 
thing to do was to create conditional (cell-type selective) knockouts by using the Cre-
LoxP recombinase system (Gu et al., 1993; Rajewsky et al., 1996; Le and Sauer, 2000). 
The EAAT2 gene was tagged by inserting a unique unidirectional DNA sequence called 
a "LoxP-site" before and after the stretch of DNA to be deleted. Genes with LoxP sites 
on each side are referred to as being "floxed" (an acronym for "flanking LoxP sites"). 
Cell selective deletion of the EAAT2 gene can then be achieved by controlling the 
expression of Cyclization recombinase (Cre). This is an enzyme that originates from 
Enterobacteria phage P1, binds to two LoxP-sites and recombines the DNA leaving only 
one loxP after deleting the sequence in between. The most common way of introducing 
expression of Cre is to cross flox-mice with Cre-mice (mice harboring the Cre gene). It 
is important to keep in mind that if Cre protein has been expressed at one point in time, 
then irreversible deletion is likely to have occurred implying that the gene is gone from 
the Cre-expressing cells as well as from all of their descendants.  
 Three different research teams generated, independently of each other, their own 
flox-EAAT2 mice (Zhou et al., 2014b; Petr et al., 2015; Aida et al., 2015). The first of 
these three mouse lines (Zhou et al., 2014b) is already available from Jackson 
Laboratory (JAX Stock No. 026619).  
 Nestin11-Cre mice (Tronche et al., 1999; Cat. no. 003771; The Jackson 
Laboratory, Bar Harbor, Maine, USA) express Cre in all of the cells that give rise to the 
nervous system, but neither in the liver nor in the endocrine pancreas. Thus, crossing 
Nestin11-Cre mice with flox-EAAT2 mice resulted in mice lacking EAAT2 in the brain 
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(Zhou et al., 2014b). These mice developed spontaneous epilepsy and died early 
similarly to the conventional knockout mice (Tanaka et al., 1997). In contrast, crossing 
with pancreas selective Cre-lines had apparently no consequences. This confirmed that 
EAAT2 plays its main roles in the nervous system and a role in pancreatic insulin 
secretion was ruled out (Zhou et al., 2014b). 
 The next step was to delete EAAT2 selectively in astrocytes. This, however, was 
not straight forward. Although GFAP is an astrocyte marker in the adult brain and 
GFAP-Cre lines allow deletion in astrocytes (e.g. Marino et al., 2000; Zhuo et al., 2001), 
these lines are not fully specific for astrocytes because the GFAP promotor is active 
also in radial glia which gives rise to virtually all neocortical projection neurons 
(Malatesta et al., 2003). Therefore a tamoxifen inducible human glial fibrillary acidic 
protein hGFAP-CreERT2 (Casper et al., 2007) mouse line was employed. These mice 
only express Cre when both the GFAP promotor is active and when tamoxifen is 
administered. Thus, Cre-mediated expression in neurons can be avoided by injecting 
tamoxifen at postnatal day 5 or later. This resulted in mice where the levels of EAAT2 
protein in the whole forebrain were reduced to 1/5 of the normal level resulting in 
spontaneous epilepsy and increased mortality (Petr et al., 2015) albeit not quite as 
dramatic as the global knockouts. In contrast, deletion in neurons by crossing the flox-
EAAT2 mice with synapsin I promoter-driven Cre recombinase mice (Rempe et al., 
2006; Jackson Laboratory: JAX Stock No. 003966) barely affected the total brain 
EAAT2 protein levels. The mice appeared normal with normal lifespan. From this it was 
concluded that astroglial EAAT2 is the main protector against excitotoxicity (Petr et al., 
2015) in agreement with the distribution of the EAAT2 protein. 
 
10. Resealing probability favors neuronal EAAT2 in synaptosome preparations   
When brain tissue is homogenized, long cellular extensions will rupture. Nerve terminals 
(boutons) are structures with diameters typically in the range 250 - 600 nm (Sorra and 
Harris, 1998; Ventura and Harris, 1999; Furness et al., 2008), and which are connected 
via axons that have diameters considerably smaller than the diameter of the terminals. 
When an axon is pulled off, it is therefore easy to imagine that many of the terminals 
may be able to reseal and thereby preserve their transmembrane ion gradients (Gray 
and Whittaker, 1962; Whittaker, 1969; Dodd et al., 1981). In contrast, when astrocyte 
extensions are ruptured and astrocyte fragments created, then the diameter of the 
rupture site on each fragment will often be larger than the diameter of the fragment. This 
makes it plausible that the percentage of astrocyte fragments that reseal successfully 
will be considerably lower than the percentage of resealing terminals. And as long as a 
fragment is leaky, there can neither be any ion gradients to drive the transport nor any 
containment of the transported molecules. Thus, such fragments will not contribute to 
the measured uptake.  
 As explained above, while the density of EAAT2 molecules is about 10 times 
higher on astrocytes than on terminals (in stratum radiatum, hippocampus CA1), the 
plasma membrane surface areas are about the same (Furness et al., 2008). Thus, if the 
resealing probability is lower, then the 10 % of EAAT2 in terminals may contribute 
significantly to the uptake activity measured in a homogenate. In agreement, it was 
shown electron microscopically that D-aspartate accumulates preferentially (85 %) in 
the terminals in synaptosome preparations (Furness et al., 2008). This was tested using 
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conditional knockout mice: when EAAT2 was selectively deleted in neurons (using 
synapsin-Cre mice), then the uptake activity in synaptosome preparations was reduced 
to half (Petr et al., 2015; see also Fig. 4). In contrast, when EAAT2 was deleted in 
astrocytes, then there was only a minor reduction in synaptosomal uptake activity (Petr 
et al., 2015). As explained above, the most likely reason for this discrepancy between 
the distribution of EAAT2 protein molecules (mostly in astrocytes) and uptake activity 
(mostly in terminals) was that most of the astrocytic EAAT2 protein was sitting in 
membrane fragments that had not resealed. To test this, brain tissue was solubilized 
and reconstituted in liposomes as described previously (Danbolt et al., 1990; Trotti et al., 
1995). In this case all the transporters were taken out of their natural membranes 
(irrespective of whether they were in leaky or in tight compartments) and inserted into 
new membranes. Thus, all EAAT2 protein molecules would now have the same 
probability of ending up in closed membrane bounded structures. As expected, the 
uptake activity determined in the liposome assay correlated with the immunoblots. Thus, 
upon reconstitution, the quantitative dominance of the astroglial EAAT2 was revealed 
(Petr et al., 2015).  
 A weakness with these experiments based on conditional knockout mice (Petr et 
al., 2015) is that the synapsin-Cre mice do not appear to express Cre in all neurons. 
This implies that the reduction observed is likely to be an underestimation (Y. Zhou and 
N.C. Danbolt, manuscript in preparation) and may explain why deletion is neurons using 
synapsin-Cre resulted in a lower reduction of synaptosomal uptake (about half) than 
expected from the D-aspartate uptake experiments described above (85 %; Furness et 
al., 2008; Section 7).  
 Nevertheless, these experiments showed that the synaptosome assay mostly 
detects neuronal components as originally assumed (Gfeller et al., 1971; Logan and 
Snyder, 1972; Levi and Raiteri, 1973a; Levi and Raiteri, 1973b; Fonnum, 1984; 
Erecinska et al., 1996; Robinson, 1998; Raiteri and Raiteri, 2000) despite contamination 
from astrocytes (e.g. Delaunoy et al., 1979; Henn et al., 1976; Nakamura et al., 1993). 
Further, these data do not give any indications that nerve terminal EAAT2 is more active 
than astroglial EAAT2 (Petr et al., 2015). 
 
11. Mismatch between EAAT2 distribution and sites of D-aspartate accumulation 
That nerve terminal uptake of glutamate is favored over astroglial uptake in tissue 
homogenates may, as explained in Section 10 above, simply be that the damage to 
plasma membranes during homogenization differentially affects nerve terminals and glia. 
The validity of this argument, however, is not quite as obvious in 0.3 mm thick 
hippocampal slices because glial cells in slices maintain large negative resting 
potentials, and their extensive gap junctional coupling should help to maintain the 
membrane potential and intracellular ion concentrations near normal values even if one 
particular cell is somewhat damaged (Bergles and Jahr, 1997). Consequently, it was a 
surprise to find that about half of all D-aspartate taken up by hippocampus slices occurs 
in axon-terminals considering that terminals only contain around 10 % of the EAAT2 
protein (Furness et al., 2008). One possibility could be that heteroexchange is faster 
than net uptake, but we have ruled that out as explained below (Section 12). Another 
possibility (that remains to be experimentally tested) might be loss from astrocytes as 
explained below (Section 13). 
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12. Heteroexchange is not substantially faster than net uptake   
Could the disproportionately efficient uptake into terminals in hippocampal slices 
(Furness et al., 2008) be due to heteroexchange being faster than net uptake? The 
astrocytes in the hippocampal slice preparations are believed to mostly perform net 
uptake because they maintain their transmembrane gradients (Bergles and Jahr, 1997) 
and because the internal glutamate levels are relatively low. This would favor net uptake 
which is a process whereby extracellular sodium ions and glutamate are brought into 
the cell in exchange for potassium. In contrast, we know little about the metabolic states 
of the terminals. They have much more internal glutamate and if their ion gradients 
should be weakened, then they might switch to heteroexchange mode. 
 How much glutamate is there in terminals compared to astrocytes? Although 
terminals are generally believed to have much higher glutamate levels than astrocytes, 
there is, as far as we are aware of, no comprehensive overview of the glutamate 
concentrations in the various cellular compartments in different brain regions of wildtype 
animals. It is, however, possible to do some very rough estimates by combining 
histology data from normal rats (Nafstad and Blackstad, 1966; Lehre and Danbolt, 1998) 
with available information on glutamate distribution (Ottersen, 1989; Storm-Mathisen 
and Ottersen, 1990; Torp et al., 1991; Storm-Mathisen et al., 1992; Ottersen et al., 1992; 
Ottersen et al., 1996). Based on this studies is seems reasonable to conclude that 
around 10 % of tissue glutamate is in astroglia, 70 % in glutamatergic nerve terminals 
and the remainder in other parts of the neurons.  
 Heteroexchange is a process whereby the transporters exchange external and 
internal substrate molecules in a 1:1 relationship (Levi and Raiteri, 1974; Raiteri et al., 
1975; Pines and Kanner, 1990; Zerangue and Kavanaugh, 1996a;  Kavanaugh et al., 
1997; Zhou et al., 2014a; see figure 5 in Danbolt, 2001). This process is electroneutral 
and has therefore been tricky to study with electrophysiological techniques. Further, it 
took time before it was understood how it could complicate the interpretations of binding 
assays (Pin et al., 1984; Danbolt and Storm-Mathisen, 1986a; Danbolt and Storm-
Mathisen, 1986b; Danbolt, 1994), and cell culture experiments (Volterra et al., 1996; 
O'Shea et al., 2002).  
 Heteroexchange does not contribute to glutamate clearance as there is no net 
transport, but it was argued that it might still explain the disproportionately strong 
labeling of glutamatergic terminals with D-aspartate. Thus, if externally added D-
aspartate is exchanged with internal glutamate, D-aspartate would accumulate inside 
even though the total number of substrate molecules (D-aspartate + L-glutamate) on 
either side of the membrane is unchanged. Old data based on synaptosomes indicated 
that heteroexchange is ten times faster than net uptake (Erecinska and Nelson, 1987; 
for review, see: Grewer and Rauen, 2005). There was, however, no consensus as some 
electrophysiological measurements of the transporter cycling rate using the glutamate 
transport-associated anion current argued that the anion current recovery rate is much 
slower when EAAT2 operates in the exchange mode than the transport mode (Otis and 
Kavanaugh, 2000).  
 We determined the relative rates of the two transport modes using radiolabeled 
substrates in combination with a system based on solubilized glutamate transporters 
reconstituted in liposomes (Zhou et al., 2013; Zhou et al., 2014a). Our experiments and 
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computer simulations suggested that net glutamate uptake and glutamate exchange 
have similar rates (Zhou et al., 2014a). Interestingly, we also found that the exchange 
process is voltage sensitive and that a sodium leak is present in EAAT2 due to 
transporter cycling from the outward to the inward conformation in the absence of 
glutamate (Zhou et al., 2014a; for review of the molecular functioning of sodium-coupled 
symporters see: LeVine et al., 2016).  
 Thus, the mismatch between D-aspartate accumulation and transporter 
distribution could not be explained simply by assuming that terminals perform rapid 
heteroexchange. 
 
13. A larger loss of D-aspartate from astrocytes than from terminals? 
Why did D-aspartate accumulate as fast in nerve terminals as in astroglia when 
hippocampal slices were incubated in D-aspartate (Furness et al., 2008)? As outlined 
above, we do not know. One possibility that remains to be experimentally tested is if 
astrocytes lose D-aspartate faster than terminals (Fig. 5).  
 Although heteroexchange cannot explain the strong labeling of terminals (see 
Section 12 above), it might contribute to a weakening of the labeling of astrocytes by 
inducing release from astrocytes: The internal glutamate concentrations are far higher in 
terminals than in astrocytes (see Section 12 above). Consequently, D-aspartate 
molecules entering terminals will be more outnumbered by (diluted with) L-glutamate 
present in cytosol than D-aspartate molecules entering glia. As explained above 
(Section 12), substrates (L-glutamate, L-aspartate or D-aspartate) present in the 
extracellular fluid may induce exchange-mediated release of internal substrates. 
However, because of the higher [L-Glu]/[D-Asp] ratio, glutamate is more likely to bind to 
the transporter from the inside than D-aspartate. Consequently, heteroexchange can be 
expected to mostly result in release of glutamate from terminals. In contrast, internal D-
aspartate in astrocytes will face less competition from glutamate and will therefore be 
expected to have a higher probability of being translocated out. Similarly, endogenous 
glutamate present on the outside (for instance glutamate that has been released from 
terminals) will mostly induce glutamate/glutamate exchange with terminals, and more 
frequently glutamate/D-aspartate exchange with glia. The net effect will be that D-
aspartate taken up into terminals is likely to stay there, while some of the D-aspartate 
taken up into astrocytes is likely to be released resulting in an underestimation of the 
true uptake activity. 
  Additional factors that have been proposed to contribute to leaks from astrocytes 
are channels, such as unpaired connexons (acting as functional hemichannels), 
pannexins, P2X receptors, or volume regulated anion channels (Abudara et al., 2015; 
Rovegno et al., 2015; for review see: Malarkey and Parpura, 2008). This may be more 
significant in slices than in normal healthy tissue because tissue damage (e.g. cutting of 
slices) may activate connexins (Abudara et al., 2015; Rovegno et al., 2015). However, 
the combined conductance must be lower than the capacity of the astrocytes to 
maintain their transmembrane gradients considering that astrocytes in the hippocampal 
slice preparations are able to maintain their membrane potentials (Bergles and Jahr, 
1997; Hanson et al., 2015).  
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 If D-aspartate taken up by astrocytes is partly lost due to a combination of 
mechanisms as suggested above, then this may obscure the real transport rate in 
astrocytes. D-aspartate is after all an artificial substrate. 
 
14. EAAT2 is probably expressed in terminals belonging to a variety of neurons  
EAAT2 mRNA is found in multiple neuronal populations (see Section 5.1 above for 
references). Further, D-aspartate uptake has been shown electron microscopically to 
occur in terminals, not only in the hippocampus as explained above, but also in the rat 
striatum (Gundersen et al., 1996). Futher, there are several reports claiming that EAAT2 
is expressed in axon-terminals in other parts of the CNS (Melone et al., 2009; Melone et 
al., 2011) in agreement with in-situ data (e.g. Berger and Hediger, 1998; Berger et al., 
2005).  
 Expression of EAAT2 in several types of axon-terminals is probable. There are 
many types of synapses with different properties. While most nerve terminals are too 
small to be studied directly with the patch-clamp technique, this is possible in some 
places. For instance, direct electrical recordings from retinal bipolar cell presynaptic 
terminals showed EAAT activation implying that they express functional transporters 
(Palmer et al., 2003). In contrast, direct recordings from the Calyx of Held synapse in 
the medial nucleus of the trapezoid body (MNTB) in the brainstem (von Gersdorff and 
Borst, 2002) did not show any presynaptic EAAT activity (Billups et al., 2013). 
 In agreement, when flox-EAAT2 mice are crossed with synapsin-Cre mice, then 
there is a reduction in glutamate uptake in synaptosomes in homogenates, not only 
from the hippocampus, but from the entire forebrain (Fig. 4A). This strong reduction 
cannot be explained by a loss of EAAT2 expression only in terminals from the CA3 
pyramidal cells. To explain the loss of activity in a whole forebrain homogenate, there 
must be a more extensive loss of EAAT2. And as the total EAAT2 levels were virtually 
unchanged (as determined by Western blotting; Fig. 4B), then the most likely 
explanation is loss of EAAT2 from a large number of terminals in addition to those from 
CA3 pyramidal cells.   
 The realization that synaptosome preparations measures EAAT2 in nerve 
terminals more efficiently than EAAT2 in astrocytes, is important considering that 
synaptosomes have been widely used to determine brain glutamate uptake activity 
(Danbolt, 2001; Beart and O'Shea, 2007; Sheldon and Robinson, 2007). If the 
expression of EAAT2 in nerve terminals is regulated differently from EAAT2 in 
astrocytes (which is likely), then it may be worthwhile to reanalyze old reports based on 
synaptosomes (Hardy et al., 1987; Procter et al., 1988; Felipo et al., 1989; Gilad et al., 
1990; Maddison et al., 1996; Dixon and Hokin, 1998; Zhu et al., 1998; Mitrovic et al., 
1999; Zhu et al., 1999; Azbill et al., 2000; Levenson et al., 2000; Nogueira et al., 2002; 
Xu et al., 2003; Fontella et al., 2004). Many of these findings have been forgotten after 
later studies have used methods that detect total tissue EAAT2 (e.g. immunoblots).  
 
15. EAAT2 in terminals will short-circuit the glutamate-glutamine cycle 
The physiological roles of EAAT2 in terminals remain to be determined. One obvious 
function would be direct recycling of transmitter glutamate (Fig. 5A).  
 The prevailing view, however, has been that glutamine released from astrocytes 
is the predominant source of glutamate in glutamatergic terminals (Van den Berg and 
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Garfinkel, 1971; Benjamin and Quastel, 1972; Hertz et al., 1999; Sibson et al., 2001) 
especially in situations of high demand such as persistent epileptiform activity (Tani et 
al., 2010; Tani et al., 2014). The idea has been that glutamate is taken up by astrocytes, 
converted to glutamine by the action of the astroglial enzyme glutamine synthetase (GS) 
in an ATP-dependent manner, released, taken up by axon-terminals and converted 
back to glutamate by means of phosphate activated glutaminase (Erecinska and Silver, 
1990; Marcaggi and Coles, 2001; Hertz, 2013).  
 This hypothesis implies that the supply of glutamine to terminals keeps up with 
glutamate release and that may not always be the case (Waagepetersen et al., 2005; 
Kam and Nicoll, 2007; Marx et al., 2015). Further, a considerable fraction of glial 
glutamate is degraded via the TCA-cycle or by deamination (Bak et al., 2006; McKenna, 
2007; Pardo et al., 2011; Marx et al., 2015).  
 Glutamine can be released to the extracellular fluid, but the exact mechanisms 
are still being discussed. This may be by means of neutral amino acid transporters in 
the astrocytic membrane (Mackenzie and Erickson, 2004; Nissen-Meyer et al., 2011; 
Hamdani et al., 2012; Bhutia and Ganapathy, 2015), but there are several possible 
mechanisms including channels (for review see: Malarkey and Parpura, 2008).  
 There is also no consensus with respect to the mechanism whereby glutamine 
can enter the terminals. No glutamine transporter protein has so far been positively 
identified in terminals in brain tissue (Mackenzie and Erickson, 2004; Conti and Melone, 
2006; Zhou and Danbolt, 2014; Grewal et al., 2009). One possibility is that they have 
evaded detection in glutamatergic terminals due to methodological challenges. Another 
possibility is that they have not been detected simply because they are not there. A third 
possibility is that the focus has been on the wrong transporters. After all, there are at 
least 14 different solute carrier proteins with the ability to transport glutamine (Bhutia 
and Ganapathy, 2015). For instance SNAT7 (slc38a7) and SNAT8 (slc38a7) have 
recently been reported to be expressed in axon-terminals (Hagglund et al., 2011; 
Hagglund et al., 2015). In line with this, there is electrophysiological evidence for 
glutamine uptake at the Calyx of Held synapse (Billups et al., 2013). As mentioned 
above (see Section 14), this synapse is special with a giant nerve terminal and may 
therefore not be representative for the majority of synapses. A problem with the majority 
of synapses is that the boutons are so small that they are difficult to study (von 
Gersdorff and Borst, 2002), and as a consequence, we know less about them.   
 Other sources of transmitter glutamate comprise de novo synthesis (Hassel and 
Bråthe, 2000; McKenna et al., 2000), and, as described in this review, direct uptake by 
EAAT2 glutamate transporters in the terminals themselves (Furness et al., 2008). The 
relative contributions of the various mechanisms are still debated and a complicating 
factor is that this may differ between brain regions and in disease. Marx and co-workers 
has recently tried to put available quantitative data together (Marx et al., 2015). This is 
an informative an easy to read review and an excellent guide for further data collection 
and discussions. 
 
16. Conclusions 
The total content of EAAT2 in the normal young adult rat brain is about 1 mg/gram 
tissue and about 100 times higher than that of EAAT3. The levels of EAAT4 are even 
lower than those of EAAT3. EAAT2 accounts for around 95 % of the total glutamate 
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uptake activity, and complete lack of EAAT2 results in a serious phenotype starting (in 
the mouse) at the end of the second week with lower body weight and hyperactivity 
developing into spontaneous epilepsy and increased lethality from the third week. About 
90 % of EAAT2 is astroglial and about 10 % is present in axon-terminals in the rat 
hippocampus CA1. This explains the high EAAT2 mRNA levels in CA3 pyramidal 
neurons. Selective deletion of EAAT2 in astrocytes gives a phenotype resembling that 
of the global knockout, while selective deletion in neurons has as yet unidentified 
consequences implying that most of the brain glutamate uptake is due to EAAT2 in 
astrocytes. EAAT3 is selectively expressed in neurons, but expressed at much lower 
levels that EAAT2 and targeted to the somato-dendritic compartments while neuronal 
EAAT2 is targeted to the axon-terminals. More than half of the uptake measured in 
synaptosome preparations is due to EAAT2 in terminals while most of the remainder is 
due to EAAT2 in glia. EAAT2 in terminals would be expected to make a contribution to 
the recycling of glutamate (and thereby short-circuit the so called glutamate-glutamine 
cycle), but how important this is compared to other sources of glutamate remains to be 
determined. Most of these data, however, are from the hippocampus so more work is 
required before we can be absolutely sure about the presence of EAAT2 in terminals in 
other brain regions. EAAT4 is also selectively neuronal, but only expressed in cerebellar 
Purkinje cells and in scattered neurons in the cerebral cortex, while EAAT1 is selectively 
astrocytic in the brain. After all these years, we do not yet have a complete picture of 
what physiological roles the various glutamate transporters play. 
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Figure legends 
 
Figure 1. Diagrammatic representation of lesions of the neocortex made to destroy the 
cell bodies that give rise to the glutamatergic corticostriatal fibers. When the neocortex 
is removed, the axon-terminals projecting to the striatum degenerate. This results in a 
strong reduction in synaptosomal glutamate uptake activity in striatum on the lesioned 
side. However, there is also a reduction in the expression of EAAT1 and EAAT2 in the 
striatum (Levy et al., 1995). This motivated investigation into whether neurons influence 
expression of EAAT2 in astrocytes (see Fig 2). (Modified from a figure provided by Line 
ML Boulland. Copyright: Neurotransporter AS, Oslo, Norway; Reproduced with 
permission). 
 
Figure 2.  When cultured separately (upper row), glial cells do not express EAAT2, 
while neurons do. On the other hand, if neurons are cultured together with astrocytes, 
then EAAT2 expression is turned on in astrocytes and decreased in neurons. This 
influence does not require direct cell-to-cell contact, as the stimulating effect is seen 
after transferring cell free conditioned medium from neuronal cultures to the glial ones 
(Gegelashvili et al., 1996; Gegelashvili et al., 2000; Plachez et al., 2000; Martinez-
Lozada et al., 2016). (Copyright: Neurotransporter AS, Oslo, Norway; Reproduced with 
permission). 
 
Figure 3. Evidence for neuronal expression of EAAT2 in terminals and synaptosomes. 
Panel a: A section from a hippocampal slice incubated in D-Asp, fixed and embedded 
for transmission electron microscopy and immunogold labelled for D-Asp uptake. Half of 
the gold particles are in a nerve terminal (t) which is forming a synapse with a spine (sp). 
Other particles lie over astrocyte profiles. Scale bar = 200 nm. Panel b: Immunogold 
labelling for EAAT2 localizes to the membranes of an isolated synaptosome (arrows) 
identifiable by the presence of vesicles internally (syn). Other membrane profiles that 
can be seen to be labelled are probably derived from glia. Scale bar = 200 nm. Panel c: 
After incubation of synaptosome preparations with D-Asp, immunogold labelling of the 
latter reveals uptake into synaptosomes, identifiable as before by vesicles internally 
(syn) and by the presence of a spine fragment forming an intact synapse with the 
synaptosome. Scale bar = 100 nm. From the same material as in (Furness et al., 2008) 
(Copyright: Neurotransporter AS, Oslo, Norway; Reproduced with permission). 
 
Figure 4. Selective deletion of EAAT2 in neurons resulted in a major reduction (to about 
half) of the glutamate uptake activity in a crude synaptosome containing homogenate 
prepared from the forebrain (A). GABA uptake was normal in all cases. Despite the 
reduction in uptake activity in the forebrain homogenate, Western blots (B) showed that 
the total EAAT2 levels were virtually unchanged. Note that the synapsin-Cre mice do 
not express Cre in all of their neurons (Y. Zhou and N.C. Danbolt, manuscript in 
preparation). Consequently, the observed reduction represents an underestimation. 
Method: mice with floxed EAAT2-gene (Zhou et al., 2014b) were crossed with synapsin-
Cre mice (Zhu et al., 2001; Jackson Laboratories, cat.no 003966). The Western blot 
with the above homogenates (B) was probed with anti-B493 antibodies to EAAT2 (RED; 
antibody-id #8; Sheep; Li et al., 2012) and with anti-A522 antibodies to EAAT1 (GREEN; 
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antibody-id #314; Rabbit; Holmseth et al., 2009). (Copyright: Neurotransporter AS, Oslo, 
Norway; Reproduced with permission). 
 
Figure 5. Schematic illustration of (A) in vivo handling of glutamate (Glu) and (B) 
uptake of D-aspartate (D-Asp) when hippocampal slices is incubated with D-Asp. Panel 
A: Glutamate present in the extracellular space may be taken up into terminals by 
means of EAAT2 directly or via EAAT2 (and EAAT1) present in astrocytes and 
subsequent relocation. Astrocytes have higher densities of EAAT2 than terminals (Table 
1) and the more serious consequences of deleting EAAT2 in astrocytes than in neurons 
suggest that astrocytes in vivo take up more glutamate than terminals (Petr et al., 2015). 
Glutamate taken up into astrocytes may be converted to glutamine by the action of the 
enzyme glutamine synthetase (GS) or be degraded (e.g. via the TCA-cycle; McKenna, 
2007). The glutamine produced can be released to the extracellular fluid, taken up 
neurons and converted back to glutamate. However, there is no consensus with respect 
to the glutamine transporters involved. Other sources of transmitter glutamate comprise 
de novo synthesis (Hassel and Bråthe, 2000; McKenna et al., 2000), and, as described 
in this review, direct uptake by EAAT2 glutamate transporters in the terminals 
themselves (Furness et al., 2008). The relative contributions of the various mechanisms 
are still debated and a complicating factor is that this may differ between brain regions 
and in disease. The contribution by EAAT3 is believed to be minor due to lower 
expression levels (Holmseth et al., 2012b). PANEL B: When hippocampal slices are 
incubated with D-Asp, then D-Asp is taken up by a combination of net uptake and 
heteroexchange. D-Asp will start accumulating in both terminals and glia with apparently 
similar rates despite much higher transporter densities in the latter. However, in contrast 
to glutamate, D-Asp will remain D-Asp because it is hardly metabolized. Once inside 
terminals, D-Asp will be diluted in excess glutamate. Therefore, when an internal 
substrate is exchanged with external D-Asp, then it will mostly be internal glutamate 
rather than D-Asp that goes out. In contrast, internal D-Asp in glia will have a higher 
probability of going out simply because there is less of the alternative (namely 
glutamate which has been metabolized). Further, any glutamate released from terminals 
will for the same reason tend to deplete glia more than terminals. If there should be 
some disconnection of gap junctions (to form hemichannels) or activation of volume 
activated anion channels, then this will also contribute to making the loss of D-Asp from 
glia higher than the loss from terminals. (Copyright: Neurotransporter AS, Oslo, Norway; 
Reproduced with permission). 
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Table 1. Tissue concentrations of glutamate transporters in the hippocampus 
(stratum radiatum, CA1) of young adult Wistar rats    
 mg EAAT 
protein 
per g 
tissue 
µmol 
EAAT 
protein 
per liter 
EAAT 
molecules 
per µm3 
tissue 
Plasma 
membranes 
per tissue 
volume 
(µm2/µm3) 
Location Maximum EAAT 
molecules per 
µm2 plasma 
membrane 
EAAT1 0.32  5.3   3200 1.4  Astroglia 2300 
EAAT2 1.3 21 12000 1.4  Astroglia 7500 
    ~1 Terminals 750 
EAAT3 0.013 0.22     130 1.5 Dendrites 90 
The above data only give an indication of the average transporter densities because 
expression levels are subject to regulation (Martinez-Lozada et al., 2016). For instance, 
EAAT3 is to a large extent present intracellularly in the brain while most of EAAT2 and 
EAAT1 are at the surface (for details see the original articles: Dehnes et al., 1998; Lehre and 
Danbolt, 1998; Furness et al., 2008; Holmseth et al., 2012b). 
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Highlights 
- A review of expression of glutamate transporters in neurons 
- EAAT2 accounts for 95 % of Glu uptake activity and 1 % of forebrain protein 
- Most of EAAT2 is in glia, but a small proportion is present in terminals 
- EAAT3 in neuronal cell bodies and dendrites, and EAAT2 in axon-terminals 
- Synaptosome preparations measure mostly neuronal EAAT2    
